We are currently recruiting patients with mild to moderate Alzheimer's disease to participate in a clinical trial.

Your participation will allow scientists to evaluate an investigational new drug, bapineuzamab (AAB-001, ELN115727), that may slow down the progression of Alzheimer’s disease.

Eligibility Requirements

Qualified participants must be 50 to 88 years old, in stable health, and have someone to accompany them to study visits.

Volunteers will be allowed to continue use of Aricept®, Razadyne®, Exelon®, and/or Namenda®.

Compensation

Qualified participants will receive study related laboratory tests, study drug, MRI brain scans, and psychiatric and memory evaluations at no cost. A transportation allowance is available.

For more information, contact Marilyn Aiello at 919-681-3949.